General and Administrative (G&A) Expenses. G&A expenses were $18.9 million for the year ended Dec. 31, 2025, compared to $20.2 million for the year ended Dec. 31, 2024. The decrease was primarily due ...
Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain Delivery TM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results